Advanced search
Publication Cover
OncoImmunology Volume 1, 2012 - Issue 7
Submit an article Journal homepage
437
Views
4
CrossRef citations to date
0
Altmetric
Author's View

Activation of systemic antitumor immunity via TRAIL-induced apoptosis

Britnie R. James Microbiology, Immunology, and Cancer Biology Ph.D. Program; University of Minnesota; Minneapolis, MN USA
&
Thomas S. Griffith Microbiology, Immunology, and Cancer Biology Ph.D. Program; University of Minnesota; Minneapolis, MN USA; Center for Immunology; University of Minnesota; Minneapolis, MN USA; Department of Urology; University of Minnesota; Minneapolis, MN USACorrespondence[email protected]
Pages 1178-1180 | Received 27 Apr 2012, Accepted 04 May 2012, Published online: 01 Oct 2012

References

  • Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3:673 - 82; http://dx.doi.org/10.1016/1074-7613(95)90057-8; PMID: 8777713
  • Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol 2000; 165:2886 - 94; PMID: 10946322
  • Griffith TS, Broghammer EL. Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus. Mol Ther 2001; 4:257 - 66; http://dx.doi.org/10.1006/mthe.2001.0439; PMID: 11545617
  • Shirota H, Klinman DM. CpG-conjugated apoptotic tumor cells elicit potent tumor-specific immunity. Cancer Immunol Immunother 2011; 60:659 - 69; http://dx.doi.org/10.1007/s00262-011-0973-y; PMID: 21318638
  • VanOosten RL, Griffith TS. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy. Cancer Res 2007; 67:11980 - 90; http://dx.doi.org/10.1158/0008-5472.CAN-07-1526; PMID: 18089829
  • Norian LA, Kresowik TP, Rosevear HM, James BR, Rosean TR, Lightfoot AJ, et al. Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapy. PLoS One 2012; 7:e31085; http://dx.doi.org/10.1371/journal.pone.0031085; PMID: 22312440
  • Holoch PA, Griffith TS. TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol 2009; 625:63 - 72; http://dx.doi.org/10.1016/j.ejphar.2009.06.066; PMID: 19836385
  • Yamano T, Ura K, Morishita R, Nakajima H, Monden M, Kaneda Y. Amplification of transgene expression in vitro and in vivo using a novel inhibitor of histone deacetylase. Mol Ther 2000; 1:574 - 80; http://dx.doi.org/10.1006/mthe.2000.0074; PMID: 10933982
  • VanOosten RL, Moore JM, Karacay B, Griffith TS. Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression. Cancer Biol Ther 2005; 4:1104 - 12; http://dx.doi.org/10.4161/cbt.4.10.2022; PMID: 16096370
  • Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002; 1:287 - 99; http://dx.doi.org/10.1038/nrd772; PMID: 12120280

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.